| |
Each year, more than 5,000 people in the U.S. are diagnosed with amyotrophic lateral sclerosis (ALS), commonly known as “Lou Gehrig’s disease.” ALS is a progressive neurological disorder resulting in the degeneration of motor nerve cells that control voluntary movement. UCSF Fresno offers one of the most comprehensive, multidisciplinary treatment facilities in the country for patients with neurodegenerative disorders such as ALS. Leading scientists and clinicians from nearly all of the major medical centers in California met at UCSF Fresno recently for the fourth annual California ALS Research Summit. Advances in research aimed at treating ALS and opportunities for collaboration on clinical trials were discussed. The UCSF Fresno Division of Neurology and the Central California Neuroscience Institute hosted the summit with funding provided by Golden West chapter of the ALS Association and California Institute of Regenerative Medicine.
Email Brandy Nikaido at bnikaido@fresno.ucsf.edu with comments and suggestions |
